NEW YORK (GenomeWeb News) – Helicos BioSciences cut its second-quarter net loss significantly on lower R&D and SG&A costs, according to the firm's quarterly filing with the US Securities and Exchange Commission.

The Cambridge, Mass.-based firm reported total revenues of $371,000 for the three-month period ended June 30, up from $251,000 for the second quarter of 2008. It said that $213,000 of its revenues in Q2 2009 came from a government research grant, while $158,000 came from product revenue, which primarily consisted of reagent sales.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.